Antigen-specific immune tolerance has been a long-standing goal for immunotherapy for the
treatment of autoimmune diseases and allergies and for the prevention of allograft rejection …

Current treatments to control pathological or unwanted immune responses often use broadly
immunosuppressive drugs. New approaches to induce antigen-specific immunological …

Tolerogenic immunotherapy aims to blunt pathogenic inflammation without affecting
systemic immunity. However, the anti-inflammatory drugs and immunosuppressive biologics …

Highlights•Vast potentials of combining nanoparticles with immune therapy.•Nanoparticles
as adjuvants or carriers for vaccination and targeted therapies.•Disease therapies using …

Vaccination using nanocarrier-based delivery systems has recently emerged as a promising
approach for meeting the continued challenge posed by infectious diseases and cancer. A …

Subunit vaccination benefits from improved safety over attenuated or inactivated vaccines,
but their limited capability to elicit long-lasting, concerted cellular and humoral immune …

Targeting the immune system with nanomaterials is an intensely active area of research.
Specifically, the capability to induce immunosuppression is a promising complement for …

The development of nanomaterials to induce antigen-specific immune tolerance has shown
promise for treating autoimmune diseases. While PEGylation has been widely used to …

Recent studies have demonstrated great therapeutic potential of educating and unleashing
our own immune system for cancer treatment. However, there are still major challenges in …

Tolerogenic nanoparticles (NPs) are rapidly being developed as specific immunotherapies
to treat autoimmune disease. However, many NP-based therapies conjugate antigen (Ag) …